Coiled Therapeutics plc
COIL · AIM · Health Care · mcap £32m · 6.1p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 01 Oct 26 | Investor Presentation via Engage Investor
Coiled Therapeutics (AIM: COIL) (OTCQB: COTXF), the clinical-stage precision oncology company developing differentiated small molecule therapies for genetically defined cancers, announces that the leadership team will ho |
−1.3% | |
| 30 Sep 26 | Participation in The Small Cap Showcase
Coiled Therapeutics (AIM: COIL) (OTCQB: COTXF), the clinical-stage precision oncology company developing differentiated small molecule therapies for genetically defined cancers, announces that members of its executive ma |
+0.0% | |
| 28 Sep 26 | Results | Half-year Results
Coiled Therapeutics plc (AIM: COIL / OTCQB: COTXF), the clinical-stage precision oncology company developing differentiated small molecule therapies for genetically defined cancers, announces its interim results for the |
+0.0% |
| 21 Sep 26 | Successful Enrolment Completed Across Two Cohorts
Successful Enrolment Completed Across Two Cohorts of New AO-252 Formulation |
+0.0% | |
| 01 Sep 26 | Appointment of Joint Corporate Broker
Coiled Therapeutics (AIM: COIL) (OTCQB: COTXF), the clinical-stage precision oncology company developing differentiated small molecule therapies for genetically defined cancers, is pleased to announce the appointment of |
+0.0% | |
| 03 Aug 26 | First Patient Dosed with new Formulation of AO-252
First Patient Dosed with Optimised Lipid-Based Formulation of AO-252 |
+0.0% | |
| 07 Jul 26 | Coiled Advances Next-Generation AO-252 Formulation
Lipid-Based Softgel Designed to Optimise Drug Exposure Ahead of Dose Expansion |
+5.3% | |
| 24 Jun 26 | Company Presentation
Coiled Therapeutics (AIM: COIL) (OTCQB: COTFX), the clinical-stage oncology company developing precision medicines for hard-to-treat cancers, announces that ahead of its presentation at the Proactive One2One Investor For |
+0.0% | |
| 24 Jun 26 | Board change | Appointment of Independent Non-Executive Director
Seasoned biotech and capital markets leader joins the Board |
+0.0% |
| 19 Jun 26 | Life Sciences Investor Forum
Coiled Therapeutics (AIM: COIL) (OTCQB: COTXF), the clinical-stage oncology company developing precision medicines for hard-to-treat cancers, announces that the Company's Chairman Sotirios Stergiopoulos will present at t |
+0.0% | |
| 18 Jun 26 | Proactive One2One Investor Forum
Coiled Therapeutics (AIM: COIL, OTCQB: COTXF), the clinical-stage oncology company developing precision medicines for hard-to-treat cancers, announces that it will be presenting at the Proactive One2One Investor Forum (t |
+0.0% | |
| 17 Jun 26 | Grant of Share Options
Coiled Therapeutics (AIM:COIL) (OTCQB: COTXF), the clinical-stage oncology company developing precision medicines for hard-to-treat cancers, announces it has granted 6,200,000 share options ("Options") over the Company's |
+0.0% | |
| 17 Jun 26 | Establishment of Medical Advisory Board
Leading Oncology Drug Developers Join Coiled Therapeutics Medical Advisory Board to Support AO-252 Clinical Development |
+0.0% | |
| 08 Jun 26 | Appointment of Ozgur Sahin as Scientific Advisor
Appointment of Professor Ozgur Sahin as Scientific Advisor |
+0.0% | |
| 19 May 26 | Commencement of Trading on US OTCQB Venture Market
Commencement of Trading on US OTCQB Venture Market |
+14.3% | |
| 07 May 26 | Attendance at Endless Frontier Labs 2026
Coiled Therapeutics to Showcase AO-252 at Prestigious Endless Frontier Labs 2026 Event |
+0.0% | |
| 07 May 26 | Board change | Appointment of Non-Executive Director
Coiled Therapeutics plc (AIM: COIL), the clinical-stage oncology company developing precision medicines for hard-to-treat cancers, announces the appointment of Dr Andrew Dean as Non-Executive Director with immediate effe |
+0.0% |
| 06 May 26 | Results | Annual Report & Financial Statements
Coiled Therapeutics plc (AIM: COIL), the clinical-stage oncology company developing precision medicines for hard-to-treat cancers, formerly Roquefort Therapeutics plc, announces its audited results for the year ended 31 |
+0.0% |
| 15 Apr 26 | Presentation at 18th Annual World Cancer Congress
Presentation at the 18th Annual World Cancer Congress |
+0.0% | |
| 08 Apr 26 | Clinical Trial Update
Enhanced Efficacy Signal and Strategic Transition to Dose Expansion |
+8.8% | |
| 27 Mar 26 | Readmission - Roquefort Therapeutics Plc
NOTICE OF CANCELLATION OF ADMISSION TO TRADING ON THE LONDON STOCK EXCHANGE |
−90.0% | |
| 26 Mar 26 | Investor Presentation
Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company, announces that following the General Meeting held earlier today at which shareholders approved the acquisition of the exclusive worldwide licence |
−5.0% | |
| 25 Mar 26 | Lyramid SPA & MK Cell License Update
Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company, announces it has agreed to extend the Longstop Dates (defined below) in relation to the binding share purchase agreement ("Lyramid SPA") for the s |
+5.3% | |
| 02 Mar 26 | Schedule One - Roquefort Therapeutics PLC
Roquefort will be renamed Coiled Therapeutics plc ("Coiled") upon the completion of the acquisition of the AO-252 Licence from A2A Pharmaceuticals, Inc. |
+12.0% | |
| 02 Mar 26 | Fundraise | Proposed Acquisition and Fundraise of £8.5 million
Proposed Acquisition and Conditional Fundraise of £8.5 million |
+12.0% |
| 25 Feb 26 | Transaction Update & Notice of Intention to Delist
Transaction Update & Intention to delist from the Main Market |
−9.1% | |
| 15 Jan 26 | Research Note Published
Roquefort Therapeutics plc (LSE:ROQ), the Main Market listed biotech company, announces that a new research note regarding the Company's proposed transaction with Coiled Therapeutics, Inc. and A2A Pharmaceuticals, Inc., |
+8.3% | |
| 12 Dec 25 | Clinical Trial & License Agreement Update
Roquefort Therapeutics plc (LSE:ROQ), the Main Market listed biotech company, announces that the binding exclusive license agreement with Coiled Therapeutics, Inc. |
+0.0% | |
| 09 Dec 25 | Conversion of CLNs
Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company, announces that the Company has received notices, in two tranches, to convert a total face value of £80,000 convertible loan notes (the "CLNs") res |
−3.7% | |
| 01 Dec 25 | Ex-Entitlement Date - Unlisted RNV Shares
Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company, announces that further to the Company's announcement earlier today confirming that the record date for determining entitlement to the Unlisted Red |
−19.5% | |
| 01 Dec 25 | Determination of Record Date and Entitlement
Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company, announces that, following the announcement on 3 November 2025 regarding the proposed issue of new unlisted redeemable non-voting shares ("Unlisted |
−19.5% | |
| 18 Nov 25 | Executed License Agreement & Transaction Update
Roquefort Therapeutics plc (LSE:ROQ), the Main Market listed biotech company, is pleased to announce that further to the announcements made on 8 September, 16 October and 3 November 2025, the Company has entered into a b |
+8.8% | |
| 03 Nov 25 | MK Cell Out-License & Lyramid SPA Update
Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company, announces it has entered into an agreement to out-license its MK Cell patents to Pleiades Pharma Ltd ("Pleiades") in return for up to US$25 millio |
−8.1% | |
| 16 Oct 25 | Fundraise | Fundraise & Transaction Update
Roquefort Therapeutics plc (LSE:ROQ), the Main Market listed biotech company, is pleased to announce that it has raised funds of £300,000, with £200,000 by way of advance subscription agreements ("Advance Subscriptions") |
−2.3% |
Company filings. Not investment advice.